Literature DB >> 21106363

Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.

Katrien De Bock1, Sandra Cauwenberghs, Peter Carmeliet.   

Abstract

As a result of excessive production of angiogenic molecules, tumor vessels become abnormal in structure and function. By impairing oxygen delivery, abnormal vessels fuel a vicious cycle of non-productive angiogenesis, which creates a hostile microenvironment from where tumor cells escape through leaky vessels and which renders tumors less responsive to chemoradiation. While anti-angiogenic strategies focused on inhibiting new vessel growth and destroying pre-existing vessels, clinical studies showed modest anti-tumor effects. For many solid tumors, anti-VEGF treatment offers greater clinical benefit when combined with chemotherapy. This is partly due to a normalization of the tumor vasculature, which improves cytotoxic drug delivery and efficacy and offers unprecedented opportunities for anti-cancer treatment. Here, we overview key novel molecular players that induce vessel normalization.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106363     DOI: 10.1016/j.gde.2010.10.008

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  72 in total

Review 1.  EGFL7: a unique angiogenic signaling factor in vascular development and disease.

Authors:  Donna Nichol; Heidi Stuhlmann
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

Review 2.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 3.  Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.

Authors:  Ning Zhu; Shanshan Weng; Juan Wang; Jiaqi Chen; Linzhen Yu; Xuefeng Fang; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

4.  R-Ras protein inhibits autophosphorylation of vascular endothelial growth factor receptor 2 in endothelial cells and suppresses receptor activation in tumor vasculature.

Authors:  Junko Sawada; Fangfei Li; Masanobu Komatsu
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

Review 5.  Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Matrix Biol       Date:  2015-04-22       Impact factor: 11.583

6.  Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.

Authors:  Melania Dovizio; Stefania Tacconelli; Emanuela Ricciotti; Annalisa Bruno; Thorsten Jürgen Maier; Paola Anzellotti; Luigia Di Francesco; Paola Sala; Stefano Signoroni; Lucio Bertario; Dan A Dixon; John A Lawson; Dieter Steinhilber; Garret A FitzGerald; Paola Patrignani
Journal:  J Pharmacol Exp Ther       Date:  2012-01-19       Impact factor: 4.030

Review 7.  Considerations for successful cancer immunotherapy in aged hosts.

Authors:  V Hurez; Á S Padrón; R S Svatek; T J Curiel
Journal:  Clin Exp Immunol       Date:  2016-11-07       Impact factor: 4.330

8.  Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Authors:  Á Ordóñez-Navadijo; E Fuertes-Yebra; B Acosta-Iborra; E Balsa; A Elorza; J Aragonés; M O Landazuri
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems.

Authors:  Min Wu; Hermann B Frieboes; Steven R McDougall; Mark A J Chaplain; Vittorio Cristini; John Lowengrub
Journal:  J Theor Biol       Date:  2012-12-07       Impact factor: 2.691

10.  Caloric restriction reduces edema and prolongs survival in a mouse glioma model.

Authors:  Yong-Sheng Jiang; Fu-Rong Wang
Journal:  J Neurooncol       Date:  2013-05-24       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.